NCT06656676 WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women
| NCT ID | NCT06656676 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | HIV Prevention |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-01-29 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2025-01-29 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
HIV prevalence among transgender women (TW) in the United States is high (\~14%). The best way to reduce HIV incidence in this population is to link TW to HIV pre-exposure prophylaxis (PrEP), which can reduce HIV transmission by up to 86%, with optimal adherence. The FDA approved the first long-acting form of PrEP, injectable cabotegravir (CAB-LA), in late 2021, which has the potential to decrease HIV transmission and increase PrEP adherence among TW. The addition of CAB-LA to available PrEP options necessitates TW and PrEP service providers select the best method (oral vs injectable) for each TW. However, TW have unique concerns about PrEP (e.g., interactions with gender-affirming hormones) and report that patient/provider discussions on this medication are suboptimal. Thus, to inform this shared decision process, the proposed study builds on formative work by developing and pilot-testing "WePrEP," a PrEP-focused bilingual digital shared decision-making tool (SDMT), tailored to diverse English- and Spanish-speaking TW and PrEP service providers. WePrEP will support communication between TW and PrEP service providers as they identify the ideal PrEP product for each TW and discuss associated adherence strategies by cuing conversations on TW's unique PrEP needs/concerns and presenting pertinent information that is culturally relevant and tailored to this population. To develop and test WePrEP, the investigators will partner with the Mile High Behavioral Healthcare Transgender Center of the Rockies, a Denver-based transgender-serving organization. They will use McNulty et al.'s adapted Shared Decision-Making Model for TW to guide the iterative participatory design process we will use with a group of racially/ethnically diverse TW and PrEP service providers, to develop WePrEP; we will begin this process using prototypes created from preliminary data (Aim 1a). The investigators will rigorously assess the usability of WePrEP via simulated patient/provider discussions (Aim 1b). Next, they will pilot test WePrEP in a randomized controlled trial (RCT; N=69 TW) with 2:1 randomization. In the RCT, PrEP service providers (N=4, of which n=1 is bilingual) will use WePrEP with intervention TW to select CAB-LA or oral PrEP and discuss adherence. Other providers (N=2, of which n=1 is bilingual) will give control TW a standard of care explanation of PrEP (CDC recommendations) to help them make their PrEP choice. TW will be referred to Sheridan Health Services to start PrEP. We will assess primary (feasibility; acceptability) and secondary (potential mechanisms of action of WePrEP; preliminary impact) outcome measures using validated scales and rigorous qualitative methods (Aims 2, 3). By creating a bilingual digital SDMT to enhance communication between TW and PrEP service providers as TW choose their ideal PrEP modality, this project is likely to make a widespread and lasting impact on TW's uptake and adherence to PrEP.
Eligibility Criteria
Inclusion Criteria: Eligible participants in the transgender women group (N=69) must: * Self-identify as a transgender woman (e.g., was assigned male at birth, but currently reports a feminine gender identity) * Be between the ages of 18 and 65 * Currently live in the Denver area * Speak English or Spanish * Be HIV-negative (via Alere Determine) * Not have participated in the development of WePrEP * Not currently take PrEP, but report they are "interested in doing more to protect themselves from HIV" \*\*We note that 1/3 of our RCT participants in the transgender women's group will be Black and/or Hispanic/Latina Eligible participants in the PrEP service providers group (N=6) must: * Not have participated in the development of WePrEP * Live in the Denver area and (as a part of their employment responsibilities) discuss PrEP use with potential end-users. * Have helped at least 1 TW make a decision about PrEP (e.g., whether or not to use it, which specific PrEP modality, etc...) in the last month. Exclusion Criteria: Participants in the transgender women group are excluded if they: * Currently live with HIV * Do not meet one or more of the inclusion criteria above Participants in the PrEP service providers group are excluded if they: * Do not live in the Denver area * Do not meet one or more of the inclusion criteria above
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06656676 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 65 Years, studying HIV Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06656676 currently recruiting?
Yes, NCT06656676 is actively recruiting participants. Contact the research team at christine.rael@cuanschutz.edu for enrollment information.
Where is the NCT06656676 trial being conducted?
This trial is being conducted at Sheridan, United States.
Who is sponsoring the NCT06656676 clinical trial?
NCT06656676 is sponsored by University of Colorado, Denver. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.